British Journal of Clinical Pharmacology · 2022 · 10 citations · 20 references
PharmacyClinical PharmacyGeriatric MedicineGeriatric AssessmentGeriatric PharmacotherapyPharmacovigilanceMedication Appropriateness ReviewMedication ReviewPharmacoepidemiologyInter-rater AgreementInter-rater ReliabilityInter-rater Reliability AssessmentInterrater ReliabilityKappa StatisticMedian AgePotentially Inappropriate Prescribing CriteriaRater Agreement
AIMS: The aim of this study is to revisit the inter-rater reliability of drug treatment assessments according to the Screening Tool of Older Persons' Prescriptions (STOPP)/Screening Tool to Alert to Right Treatment (START) criteria. METHODS: Potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) were independently identified by two physicians in two cohorts of older people (I: 200 hip fracture patients, median age 85 years, STOPP/START version 1; II: 302 primary care patients, median age 74 years, STOPP/START version 2). Kappa statistics were used to evaluate inter-rater agreement. RESULTS: In cohort I, a total of 782 PIMs/PPOs, related to 68 (78%) out of 87 criteria, were identified by at least one assessor, 500 (64%) of which were discordantly identified by the assessors, that is, by one assessor but not the other. For four STOPP criteria, all PIMs (n = 9) were concordantly identified. In cohort II, 955 PIMs/PPOs, related to 80 (70%) out of 114 criteria, were identified, 614 (64%) of which were discordantly identified. For three STOPP criteria, all PIMs (n = 3) were concordantly identified. For no START criterion, with ≥1 PPO identified, were all assessments concordant. The kappa value for PIM/PPO identification was 0.52 in both cohorts. In cohort II, the kappa was 0.37 when criteria regarding influenza and pneumococcal vaccines were excluded. Further analysis of discordantly identified PIMs/PPOs revealed methodological aspects of importance, including the data source used and criteria wording. CONCLUSIONS: When the STOPP/START criteria are applied in PIM/PPO research, reliability seems to be an issue not encountered in previous reliability studies.
20
Interrater reliability: the kappa statistic
Marry L. McHugh · Biochemia Medica · 2012 · 18.6K citations · Full text
Interrater reliability: the kappa statistic.
Mary L. McHugh · PubMed · 2012 · 9.2K citations · Full text
Paul Gallagher, Cristín Ryan, Shauna E. Byrne et al. · International Journal of Clinical Pharmacology and Therapeutics · 2008 · 1.5K citations
Paul Gallagher, Jean‐Pierre Baeyens, Eva Topinková et al. · Age and Ageing · 2009 · 159 citations · Full text